Chronic expanding haematoma (CEH) is a rare type of haematoma that enlarges slowly and continuously without coagulation. It can occur following surgery because of shear stressinduced bleeding in the scar tissue between the subcutaneous fat and fascia. We present three cases of large chronic CEH that were successfully treated with triamcinolone injections. Three female patients developed large chronic CEH at 9 months, 5 years, and 6 years, respectively, after latissimus dorsi flap harvesting for breast reconstruction. Although the condition did not improve after multiple sessions of haematoma aspiration in the first two patients, it resolved following a single 40-mg triamcinolone injection along with appropriate compression dressing for several weeks. In the third patient, triamcinolone was injected immediately after the initial aspiration of the haematoma, and the condition improved considerably. There were no side effects in any of the patients. To the best of our knowledge, this is the first report of successful treatment of large CEH using triamcinolone. Therefore, we suggest that triamcinolone injections be considered for the treatment of CEH.
INTRODUCTION
Chronic expanding haematoma (CEH) is a rare type of haematoma that enlarges slowly and continuously without coagulation. In general, it gradually decreases in size and disappears naturally over time. Although the specific mechanism underlying this enlargement is not completely understood, it is thought that CEH is caused by minor blunt trauma or surgery [1] . In such cases, a small amount of shear stress-induced bleeding may occur in the scar tissue between the subcutaneous fat and fascia [2, 3] . The bleeding then continues, and the haematoma enlarges because of the accumulation of coagulation factors and degradation products of the fibrinolytic system [1] . Furthermore, because of irritation, blood and breakdown products could cause repeated exudation or bleeding from capillaries in the granulation tissue [4] . CEH can occur at any location in the body [5] , including the calf, thigh [6] , knee [7] , buttocks [8] , abdomen, pelvis [9] , and breast [10] , and may often develop in simulated neoplasms. It occurs not only in soft tissues but also in any type of cavity. It is presumed that shear force is easily generated in the back region during daily activities such as turning over during sleep and Management of Chronic Expanding Haematoma Using Triamcinolone after Latissimus Dorsi Flap Harvesting twisting at the waist while walking [5] . Therefore, reconstructive surgeons should be aware that CEH can develop in patients who undergo surgery with a latissimus dorsi flap. Three such cases of CEH at the latissimus dorsi flap site have been previously reported [5, 11, 12] . Although treatment for CEH has not yet been established, surgical excision or aspiration is commonly performed. Here, we report three cases of CEH that developed at the latissimus dorsi flap donor site between August 2012 and August 2014 at our institute; these cases improved following a triamcinolone injection, without any severe complications.
CASES
Three female patients were included in this study. Data on exposures and outcomes were obtained using chart review after the patient provided informed consent. Although the patients did not have any obvious complications immediately after the flap surgery, CEH developed in the donor site at a mean of 47 months (range, 9 months-6 years) postoperatively. This study was performed according to institutional ethical guidelines.
Treatment procedure
In the first two patients, the initial treatment consisted of multiple sessions of aspiration of the CEH in the outpatient clinic. The haematoma was drained using an indwelling needle and syringe, without the use of any anaesthesia, while the patients were seated. Then, with the patients lying in the prone position, a piece of cotton (5 cm thickness) was applied directly onto the site of CEH, a piece of gauze was laid on top of the cotton, and an elastic bandage (width, 10 cm) was wrapped over the cotton and gauze and around the body to compress the site to prevent recurrence. The patients were carefully instructed on how to change the cotton and elastic bandage themselves at home after washing. The compression dressing was basically applied 24 hours a day. However, the CEH continued to enlarge. Therefore, after draining the haematoma, 40 mg of triamcinolone diluted in 4 mL of saline was immediately injected into the draining space by using another syringe through the same indwelling needle. The same compression dressing was tightly applied for at least 1 month to ensure appropriate spread of triamcinolone and prevent recurrence. In the third patient, a 40-mg triamcinolone injection was administered immediately after the initial drainage of the haematoma, without first attempting multiple sessions of aspiration.
Case 1 (42-year-old woman)
The patient (height, 163 cm; weight, 54.0 kg) had undergone left mastectomy for breast cancer (T1N0M0 stage 1) at 39 years of age, and reconstruction surgery using a latissimus dorsi flap was performed after 4 months. The patient also suffered from systemic lupus erythematosus and was taking aspirin for thromboprophylaxis. Although the postoperative course was uneventful and no history of trauma was evident, a large mass on the back measuring 100 mm × 30 mm × 230 mm suddenly developed 9 months after the breast reconstruction surgery (Fig. 1A) . The location corresponded with the previous latissimus dorsi flap donor site. The mass was diagnosed with CEH, and the haematoma was aspirated using an indwelling needle; the total aspiration volume was 130 mL. The CEH contents contained /μL), while the haematocrit value in the blood on the same day was 34.1% (RBC count, 390 × 10 4 /μL). Although the patient stopped taking aspirin and the haematoma was aspirated three more times in 2 months, with aspirated volumes of 50 mL, 70 mL, and 200 mL, respectively, the haematoma gradually increased in size. Because 520 mL was aspirated at the fifth aspiration session, 40 mg of triamcinolone was injected into the draining space followed by appropriate compression dressing for 8 weeks. The patient's condition markedly improved without further enlargement of the CEH. Although the patient resumed taking aspirin 6 months after the triamcinolone injection, there was no recurrence or need for aspiration for 25 months (Fig. 1C) .
Case 2 (58-year-old woman)
The patient (height, 158.6 cm; weight, 70.3 kg) had undergone left mastectomy for breast cancer (TisN0M0 stage 0) at 43 years of age and breast reconstruction using a latissimus dorsi flap at 52 years of age with a good postoperative course. The patient was taking sarpogrelate hydrochloride for lumbar canal stenosis. Six years after the breast reconstruction, the patient noticed a large mass measuring 90 mm × 75 mm × 50 mm on her back (Fig. 2A) . The location corresponded with the previous latissimus dorsi donor site. The mass was diagnosed as CEH, and the patient stopped taking sarpogrelate hydrochloride. The haematoma was aspirated four times in 3 months, with aspirated volumes of 100 mL, 100 mL, 130 mL, and 190 mL (mean volume, 130 mL). The characteristics of the CEH contents suggested the presence of blood. At the fourth aspiration, 40 mg of triamcinolone was injected into the draining space followed by compression dressing for 6 weeks. The haematoma size was reduced markedly; the aspirated fluid volume fell to 10 mL at 10 days after the triamcinolone injection. However, a solid haematoma, which could not be aspirated or injected with triamcinolone, remained. Hence, surgical excision of the solid haematoma was performed 2 months after the triamcinolone injection. The excised tissue consisted of a soft cystic mass with a thick fibrous capsule containing an old blood clot and serous fluid (Fig. 2B) . Although the patient resumed taking sarpogrelate hydrochloride 6 months after the operation, there was no further CEH formation for 6 months (Fig. 2C ).
Case 3 (53-year-old woman)
The patient (height, 158.0 cm; weight, 44 kg) had undergone right mastectomy for bilateral breast cancer (T1N0M0 stage 1) at the age of 48 years. Breast reconstruction using bilateral latissimus dorsi flaps was performed at the age of 49 years. Although the postoperative course was uneventful and there was no evident history of trauma, a large mass on the right back measuring 110 mm × 60 mm × 85 mm suddenly developed 5 years after the breast reconstruction surgery (Fig. 3A) . The mass was diagnosed as CEH. The location corresponded with the right latissimus dorsi donor site, and there was no sign of CEH on the left side. The first aspiration resulted in an aspirated volume of 60 mL. Triamcinolone (40 mg) was injected immediately after this first aspiration. Although the condition subsided for 4 months, a minor recurrence of the CEH was noted. Therefore, the CEH was again aspirated, and another 40-mg triamcinolone injection was administered. There was no further CEH formation for 10 months (Fig. 3B) . 
DISCUSSION
The latissimus dorsi is a major muscle of the back. A large space is created when a portion of the latissimus dorsi muscle is harvested. In this space, a small amount of bleeding might occur due to shear stress in the scar tissue between the subcutaneous fat and fascia. Three cases of CEH in the latissimus dorsi flap donor site, with no noted history of trauma, have been previously reported [5, 11, 12] . CEH developed 1 month, 5 years, and 13 years after the flap surgery in these three cases. In our series, the haematoma developed 9 months, 5 years, and 6 years after the flap surgery in the three cases. Based on the findings of these cases, surgeons should consider that the duration between flap surgery and the development of CEH may range from months to years. In our first two cases, antiplatelet medication was administered before the operation. Acetylsalicylic acid (Bayaspirin) was orally administered in case 1; this medication is used primarily in the treatment of cardiovascular diseases, such as myocardial infarction and cerebral infarction. It acts by inhibiting cyclooxygenase and plays an important role in platelet aggregation; it acts as an antiplatelet agent by inhibiting thromboxane A2 [13] . Sarpogrelate hydrochloride (Anplag) was orally administered in case 2. It inhibits platelet aggregation and vessel constriction by selectively antagonising the serotonin receptors 5-HT2 on the vessels and platelets [14] . This improves the ischemic symptoms of chronic arterial occlusive disease, such as ulcers, pain, and cold sensation. The main side effect of these antiplatelet agents is a bleeding tendency, which could increase the risk of a postoperative haematoma, including CEH.
There are few reports regarding the treatment for CEH. However, because CEH is usually encapsulated, surgical excision or aspiration is commonly used. As described here, a triamcinolone injection could be the treatment of choice, particularly after failed aspiration attempts. Triamcinolone has previously been used to improve seroma at the latissimus dorsi flap donor site [15] . Despite a major difference in blood cell concentration, the clinical conditions of CEH and seroma after latissimus dorsi flap harvesting are relatively similar; both involve the accumulation of liquid between the skin and the underlying scar tissue and occur because of inflammation caused by postoperative shear stress. In seroma, inflammatory mediators are stimulated by tissue damage, and the exudate stagnates in the dead space. Triamcinolone is an anti-inflammatory agent that is believed to reduce the re-accumulation of a seroma. It suppresses the inflammatory process by the formation of the phospholipase inhibitor lipocortin, which diminishes the supply of arachidonic acid available for synthesis of prostaglandin and leukotrienes. As a result, capillary permeability, oedema, migration of leucocytes, and the subsequent signs of capillary proliferation and fibroblast and collagen deposition are inhibited. In CEH, the pathogenesis is considered to involve inflammation that is induced by the destructive products of hemocytes [1] . Therefore, we concluded that a localised triamcinolone injection might also be effective for CEH.
Previous reports indicate that 40-80 mg of triamcinolone should be injected in cases of seroma. On the basis of these reports, we injected 40 mg of triamcinolone at each session. Consequently, the haematoma volumes were reduced after the initial injection. Case 1 showed a marked improvement without the need for an additional triamcinolone injection, even though this case involved the largest haematoma (520 mL) among the three cases. The fluid volume of CEH also decreased in case 2, although a solid haematoma remained. Surgical resection was required for the solid haematoma. The recurrence experienced by case 3 after the first triamcinolone injection resolved with a second 40 mg triamcinolone injection. On the basis of these experiences, we recommend an initial 40-mg triamcinolone injection at the first session irrespective of the haematoma size. For recurrence, a second 40-mg triamcinolone injection is suggested. However, the most appropriate triamcinolone dose for CEH treatment should be assessed further with a larger number of cases.
In conclusion, in cases of CEH, a triamcinolone injection, rather than surgical excision or aspiration, can be considered for treatment.
